Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtrer
Plus de filtres








Gamme d'année
1.
Biol. Res ; 50: 9, 2017. tab, graf
Article de Anglais | LILACS | ID: biblio-838964

RÉSUMÉ

BACKGROUND: A number of dysregulated miRNAs have been identified and are proposed to have significant roles in the pathogenesis of type 2 diabetes mellitus or renal pathology. Alpinia oxyphylla has shown significant anti-inflammatory properties and play an anti-diabetes role. The objective of this study was to detect the alteration of miRNAs underlying the anti-diabetes effects of A. oxyphylla extract (AOE) in a type II diabetic animal model (C57BIKsj db-/db-). RESULTS: Treatment with AOE for 8 weeks led to lower concentrations of blood glucose, urine albumin, and urine creatinine. 17 and 13 miRNAs were statistically identified as differentially regulated in the DB/DB and db-/db- AOE mice, respectively, compared to the untreated db-/db- mice. Of these, 7 miRNAs were identified in both comparison groups, and these 7 miRNAs were verified by quantitative real-time PCR. Functional bioinformatics showed that the putative target genes of 7 miRNAs were associated with several diabetes effects and signaling pathways. CONCLUSIONS: These founding suggest that the potential of AOE as a medicinal anti-diabetes treatment through changes in the expressions of specific miRNAs. The results provide a useful resource for future investigation of the role of AOE-regulated miRNAs in diabetes mellitus.


Sujet(s)
Animaux , Mâle , Souris , Extraits de plantes/pharmacologie , microARN/effets des médicaments et des substances chimiques , Diabète de type 2/traitement médicamenteux , Hypoglycémiants/pharmacologie , Rein/effets des médicaments et des substances chimiques , Facteurs temps , Glycémie/analyse , Régulation de l'expression des gènes , Reproductibilité des résultats , Résultat thérapeutique , Analyse de séquence d'ARN , Créatinine/sang , microARN/métabolisme , Diabète expérimental/métabolisme , Diabète expérimental/traitement médicamenteux , Diabète de type 2/métabolisme , Néphropathies diabétiques/métabolisme , Néphropathies diabétiques/traitement médicamenteux , Albuminurie , Réaction de polymérisation en chaine en temps réel , Rein/métabolisme , Souris de lignée C57BL
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE